Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9812791 | 0.91 | KDM4E (0.39) | KDM4EMAPK1LMNAFTOAPP | |
| SCHEMBL10808734 | 0.90 | KDM4E (0.35) | KDM4EMAPK1LMNAFTO | |
| SCHEMBL1187892 | 0.89 | — | — | |
| SCHEMBL5573647 | 0.87 | KDM4E (0.39) | KDM4EMAPK1LMNAFTOAPP | |
| SCHEMBL10810437 | 0.87 | KDM4E (0.39) | KDM4EMAPK1LMNAFTOAPP | |
| SCHEMBL7796741 | 0.87 | — | — | |
| SCHEMBL9812785 | 0.87 | — | — | |
| SCHEMBL2116944 | 0.70 | — | — | |
| SCHEMBL10874735 | 0.66 | TRPA1 (0.33) | — | |
| SCHEMBL2405291 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0263138-B1 | IMPROVEMENTS IN OR RELATING TO THE TREATMENT OF SICKLE CELL DISEASE | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1991-06-12 | — | — | EP | claimed |
| EP-0263138-A1 | IMPROVEMENTS IN OR RELATING TO THE TREATMENT OF SICKLE CELL DISEASE. | NAT RES DEV (GB) | 1988-04-13 | — | — | EP | claimed |
| WO-1987005509-A1 | IMPROVEMENTS IN OR RELATING TO THE TREATMENT OF SICKLE CELL DISEASE | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-09-24 | — | — | WO | claimed |
| US-4665064-A | IN BLOOD; ZINC CHELATE | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-05-12 | — | — | US | claimed |
| EP-0263138-B1 | IMPROVEMENTS IN OR RELATING TO THE TREATMENT OF SICKLE CELL DISEASE | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1991-06-12 | — | — | EP | disclosed |
| US-4866052-A | TREATING BLOOD WITH ZINC HYDROXY YRONE COMPLETE ENHANCES OXYGE N BINDING AFFINITY | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1989-09-12 | — | — | US | disclosed |
| EP-0263138-A1 | IMPROVEMENTS IN OR RELATING TO THE TREATMENT OF SICKLE CELL DISEASE. | NAT RES DEV (GB) | 1988-04-13 | — | — | EP | disclosed |
| WO-1987005509-A1 | IMPROVEMENTS IN OR RELATING TO THE TREATMENT OF SICKLE CELL DISEASE | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1987-09-24 | — | — | WO | disclosed |